RA
European Commission approves new RA treatment from BMS
September 6, 2016Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, EMA, EU, Orencia, RA, abatacept, approval, rheumatoid arthritis
Bristol-Myers Squibb has received approval from the European Commission for rheumatoid arthritis (RA) treatment Orencia (abatacept), making it the first …
Data supports switching to Hospira biosimilar for RA
June 10, 2015Research and Development, Sales and Marketing EULAR, Hospira, Janssen, RA, brett wells, celltrion, inflectra, rome
Findings presented at EULAR this week from the first real-world study in patients with rheumatic diseases supports switching from J&J’s …
BMS backs rheumatoid arthritis prevention trial
March 27, 2015Sales and Marketing BMS, Bristol-Myers Squibb, Orencia, RA, abatacept, rheumatoid arthritis
Bristol-Myers Squibb is funding a £3 million trial of Orencia as a preventative treatment for rheumatoid arthritis. The study will …
Janssen abandons Simponi application
May 23, 2014Sales and Marketing Europe, Janssen, RA, Simponi, rheumatoid arthritis
Janssen Biologics has withdrawn its application to add an intravenous (IV) form to the marketing authorisation of veteran rheumatoid arthritis …
Humira drives AbbVie again
April 28, 2014Sales and Marketing AbbVie, Abbott, Humira, RA
Rheumatoid arthritis treatment Humira has once more driven AbbVie, bringing in more than half the company’s sales in the first …
AstraZeneca sells arthritis drug for $35 million
November 20, 2013Sales and Marketing AstraZeneca, RA, arthritis, horizon, vimovo
AstraZeneca has sold rights to its arthritis treatment Vimovo to speciality pharma firm Horizon Pharma for $35 million. AZ retains …
Orencia matches Humira
June 13, 2013Sales and Marketing AbbVie, Abbott, Humira, Orencia, RA
Bristol-Myers Squibb is hoping its biologic Orencia can grab a little more of the rheumatoid arthritis market after demonstrating non-inferiority …
GSK licences RA drug
June 5, 2013Research and Development, Sales and Marketing GSK, RA, morphosys
GlaxoSmithKline is gambling millions of euros on an investigational drug in a bid to get an edge in the fight …
AstraZeneca abandons late-stage RA drug
June 5, 2013Research and Development, Sales and Marketing AstraZeneca, RA, Rigel
AstraZeneca is to exit development of a new rheumatoid arthritis drug, after Phase III trials produced disappointing results.The Anglo-Swedish firm …
Pfizer’s Xeljanz rejected in Europe
April 28, 2013Sales and Marketing CHMP, Humira, Pfizer, RA, Xeljanz, rheumatoid arthritis
Pfizer has suffered a major setback with the rejection of its new arthritis drug in Europe.The EMA’s medicines committee the …
AbbVie guards Humira data
March 13, 2013Sales and Marketing AbbVie, Abbott, Humira, RA, transparency
AbbVie has issued two injunctions against the European Medicines Agency to prevent the regulator revealing data about rheumatoid arthritis drug …
Lilly abandons RA drug
February 8, 2013Research and Development, Sales and Marketing RA, lilly, tabalumab
Lilly is abandoning its late-stage trial into investigational rheumatoid arthritis (RA) drug tabalumab but insists the move has nothing to …
RA setbacks for AstraZeneca and Lilly
December 14, 2012Research and Development, Sales and Marketing AstraZeneca, Humira, RA, lilly
AstraZeneca and Eli Lilly have both suffered setbacks in their attempts to push their respective investigational rheumatoid arthritis (RA) treatments …
Humira continues to drive Abbott
October 22, 2012Sales and Marketing AbVie, Abbott, Humira, RA
Abbott Laboratories’ rheumatoid arthritis drug Humira has once again shown its value to the company with a strong performance in …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
